AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02405416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Portal triad clamping
Description: Portal triad are clamped in hepatectomy.
Study NCT00203203 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramyocardial Injection of stem cells via NOGA Mapping
Description: Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
Study NCT00203203 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control, then Stem Cell Therapy
Description: Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
Study NCT03128697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Satiating diet
Study NCT03128697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Study NCT00657709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)
Description: One dose of rMenB concomitantly with the routinely administered infant vaccines
Study NCT00785486 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam Alone
Description: Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
Study NCT00785486 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Qualaquin (quinine) alone steady state
Description: Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
Study NCT00785486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and Qualaquin at steady state
Description: On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
Study NCT04458064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LMA i gel
Description: insertion of LMA for maintaining airway during anesthesia
Study NCT00677495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Description: Gluten-free diet
Study NCT02422433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule Marking
Description: Marking and imaging of the esophagus using the OFDI Capsule and system.
Study NCT02193594 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative concurrent chemoradiotherapy
Description: The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
Study NCT02193594 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical D2 total gastrectomy
Description: Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
Study NCT02193594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical D2 total gastrectomy
Description: Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
Study NCT02193594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Description: Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
Study NCT02193594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA\<1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA>1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
Study NCT03440879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: Patients currently treated with Zoladex
Study NCT02141516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV
Description: 2 doses of vaccine 2 months apart
Study NCT02141516 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rMenB+OMV
Description: 2 doses of vaccine 2 months apart
Study NCT02164396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle Lens
Description: Spectacle Lens Only
Study NCT02164396 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Soft Contact Lens
Description: subject's own contact lens
Study NCT02164396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: senofilcon A or narafilcon A
Study NCT02188576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose TXA
Study NCT02188576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose TXA
Study NCT01690767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Description: Children \< 7 kg and > 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
Study NCT01690767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Health Care Lubricating Jelly
Description: Non-medicinal lubrication gel
Study NCT02678039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
Study NCT02678039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
Study NCT02364310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baroreceptor stimulation with Barostim Neo TM
Study NCT02149433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
Study NCT02149433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03945877 — intervention group
Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study NCT01486563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (Hydroxyethyl starch 130/0,4)
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study NCT01486563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9 mg/ml
Description: 7,5 ml/kg in the first hour and then 5 ml/kg
Study NCT00565279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF1057
Description: Twice daily, topical
Study NCT00565279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASF1057
Description: Twice daily, topical
Study NCT00565279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF1057
Description: Twice daily, Topical
Study NCT00565279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASF1057
Description: Twice daily, Topical
Study NCT03279276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector.
Study NCT03279276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector.
Study NCT04115358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid: Gengigel teething
Description: Applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
Study NCT04115358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol Buckley formula: Formacresol
Description: Applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
Study NCT04115358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ferric sulfate: ViscoStat
Description: Applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with stainless steel crowns and composite filling material.
Study NCT00657709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)
Description: One dose of rMenB concomitantly with the routinely administered infant vaccines
Study NCT01205165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefor dipivoxil
Description: All enrolled subjects were enrolled to adefovir dipivoxil arm.
Study NCT01049724 — intervention group
Intervention type: OTHER
Intervention: Tear collection
Description: Tear collection
Study NCT01149798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane and Cisplatin combination
Description: Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1.
Study NCT02121340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Study NCT04065919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
Study NCT04065919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine with epinephrine
Description: 0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
Study NCT00003694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Description: Given IV
Study NCT00003694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00003694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02051972 — intervention group
Intervention type: DEVICE
Intervention: Implanted with a Nanostim leadless pacemaker system
Study NCT03027466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation induction
Description: Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
Study NCT03027466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-affirmation induction
Description: Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
Study NCT00657709 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa
Description: Routine vaccination
Study NCT00657709 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: One dose of the routinely administered infant vaccines + MenC vaccine
Study NCT00657709 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: Routine vaccination
Study NCT03027466 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-affirmation induction
Description: Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition). Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
Study NCT03022617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Study NCT02172937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual Stromal Cells thawed in plasma
Study NCT04292756 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IOP
Description: Ophthalmic examination
Study NCT00502749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
Study NCT00502749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires taking 15 minutes to complete.
Study NCT00890409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling cap (YJW608-04B)
Description: A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
Study NCT02206100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER977
Description: reversal of edoxaban-induced anticoagulation
Study NCT03761251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pet Fish
Description: Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~1. feed fish one pellet in the morning after waking; check and record BG reading at that time~2. feed fish one pellet in the evening before dinner; check and record BG reading at that time~3. feed fish one pellet at night before bedtime; check and record BG reading at that time~4. every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience.
Study NCT01624727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 acid ethyl esters
Description: Lovaza 3.6 g daily
Study NCT01826175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
Study NCT01826175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
Study NCT01826175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
Study NCT01826175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
Study NCT01706250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Cleanser
Description: Available over the counter.
Study NCT01706250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (2.5% BPO) Foam Treatment
Description: Available over the counter.
Study NCT01706250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
Description: Available over the counter.
Study NCT01706250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROACTIV (2.5% BPO) Renewing Cleanser
Description: Available over the counter.
Study NCT01706250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROACTIV (2.5% BPO) Repairing Lotion
Description: Available over the counter.
Study NCT01706250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PROACTIV (2.5% BPO) Revitalizing Toner
Description: Available over the counter.
Study NCT02172937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Decidual Stromal Cells thawed in human albumin
Study NCT02085824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study NCT02085824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Study NCT02085824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran